We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Alnylam Begins Phase III Study on Onpattro for New Indication
Read MoreHide Full Article
Alnylam Pharmaceuticals, Inc. (ALNY - Free Report) announced that it has initiated a phase III APOLLO-B study on its lead drug Onpattro (patisiran) for the treatment of transthyretin amyloidosis (ATTR amyloidosis) with cardiomyopathy. The primary endpoint of this global placebo-controlled study is to see the change from baseline in the 6-minute walk test (6MWT) at month 12.
Shares of Alnylam were up almost 1.3% following this announcement on Monday. In fact, so far this year, the stock has rallied 16.2% against the industry’s decline 1.7%.
We remind investors that the FDA and the European Commission approved Onpattro, an RNAi therapeutic, for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adult patients during 2018. The drug is the first and the only FDA-approved treatment for this indication.
In June 2019, the Japanese Ministry of Health, Labour and Welfare (MHLW) approved Onpattro for the treatment of hATTR amyloidosis with polyneuropathy.
During the first half of this year, Onpattro generated sales of $64.5 million. The initial uptake of the drug has been encouraging with more than 500 patients worldwide having received Onpattro treatment since its launch as of Jun 30, 2019. Label expansion of the drug should further boost sales for the company.
Alnylam has inked several collaboration deals for the development and commercialization of its broad pipeline of RNAi therapeutic candidates. Notably, Alnylam has an alliance with Regeneron Pharmaceuticals (REGN - Free Report) to discover, develop and commercialize new RNAi therapeutics for diseases of the eye and the central nervous system.
The company also has other candidates in its pipeline. Alnylam along with partner The Medicine Company is evaluating inclisiran in phase III ORION studies for hypercholesterolemia. Alnylam also has a pact with Sanofi’s (SNY - Free Report) specialty care global business unit Genzyme.
Zacks experts released their picks to gain +100% or more in 2020. One is a famous cutting-edge food company that is “hiding in plain sight.” Swamped with competitors and ignored by Wall Street, its stock price floundered. Now, suddenly, it acquired a company that gives it an advantage none of its peers have.
Image: Bigstock
Alnylam Begins Phase III Study on Onpattro for New Indication
Alnylam Pharmaceuticals, Inc. (ALNY - Free Report) announced that it has initiated a phase III APOLLO-B study on its lead drug Onpattro (patisiran) for the treatment of transthyretin amyloidosis (ATTR amyloidosis) with cardiomyopathy. The primary endpoint of this global placebo-controlled study is to see the change from baseline in the 6-minute walk test (6MWT) at month 12.
Shares of Alnylam were up almost 1.3% following this announcement on Monday. In fact, so far this year, the stock has rallied 16.2% against the industry’s decline 1.7%.
We remind investors that the FDA and the European Commission approved Onpattro, an RNAi therapeutic, for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adult patients during 2018. The drug is the first and the only FDA-approved treatment for this indication.
In June 2019, the Japanese Ministry of Health, Labour and Welfare (MHLW) approved Onpattro for the treatment of hATTR amyloidosis with polyneuropathy.
During the first half of this year, Onpattro generated sales of $64.5 million. The initial uptake of the drug has been encouraging with more than 500 patients worldwide having received Onpattro treatment since its launch as of Jun 30, 2019. Label expansion of the drug should further boost sales for the company.
Alnylam has inked several collaboration deals for the development and commercialization of its broad pipeline of RNAi therapeutic candidates. Notably, Alnylam has an alliance with Regeneron Pharmaceuticals (REGN - Free Report) to discover, develop and commercialize new RNAi therapeutics for diseases of the eye and the central nervous system.
The company also has other candidates in its pipeline. Alnylam along with partner The Medicine Company is evaluating inclisiran in phase III ORION studies for hypercholesterolemia. Alnylam also has a pact with Sanofi’s (SNY - Free Report) specialty care global business unit Genzyme.
Zacks Rank
Alnylam currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
5 Stocks Set to Double
Zacks experts released their picks to gain +100% or more in 2020. One is a famous cutting-edge food company that is “hiding in plain sight.” Swamped with competitors and ignored by Wall Street, its stock price floundered. Now, suddenly, it acquired a company that gives it an advantage none of its peers have.
Today, see all 5 stocks with extreme growth potential >>